Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06086561 · ClinicalTrials.gov registry record · NA

Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device

A NA study of Hydrocephalus, sponsored by Rhaeos.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
4
Study locations

NCT06086561 is a NA study of Hydrocephalus that is actively recruiting participants, run by Rhaeos. The registered enrollment target is 130 participants, roughly in line with the 126-participant average among 17 other Hydrocephalus trials with a reported enrollment target. The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06086561, a NA study of Hydrocephalus, is actively recruiting participants, sponsored by Rhaeos.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
4
Study locations

Study Summary

This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow. Patients with an existing implanted shunt will wear the device to acquire longitudinal data.

Conditions Studied

Interventions

  • DEVICE Thermal Anisotropy Measurement Device

Study Locations (4)

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
  • MATTER - Chicago
  • Northwest Special Recreation Association - Rolling Meadows

Florida

  • Tampa Marriott Water Street - Tampa

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2023-11-17
Est. Completion 2025-12
Phase NA

Sponsor

Rhaeos

15 total trials

What the Registry Record Tells You About NCT06086561

The ClinicalTrials.gov registry entry for NCT06086561 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 126-participant average among 17 other Hydrocephalus trials with a reported enrollment target. The listed sponsor is Rhaeos, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hydrocephalus appearing as the primary indexed condition, and to 1 intervention - of which Thermal Anisotropy Measurement Device is the first listed.

NCT06086561 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT06086561 about?

NCT06086561 is a clinical study titled "Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device". This study evaluates the performance of a device for non-invasively assessing cerebrospinal fluid (CSF) shunt flow. Patients with an existing implanted shunt will wear the device to acquire longitudinal data.

What is the current status of trial NCT06086561?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2023-11-17. Estimated completion is 2025-12.

What conditions does trial NCT06086561 study?

This clinical trial studies the following conditions: Hydrocephalus.

What interventions are being tested in trial NCT06086561?

The interventions under investigation include: Thermal Anisotropy Measurement Device (DEVICE).

Who is sponsoring clinical trial NCT06086561?

This trial is sponsored by Rhaeos, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06086561 being conducted?

This trial has 4 study locations across Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hydrocephalus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.